Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.
Richard, a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa, talks about the changes MCO-010 treatment has made in his life.
Hear how a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa feels about his experience two years after being enrolled in the study.
Hear what a Stargardt Macular Degeneration patient in our STARLIGHT Clinical Trial has to say about her experience.
Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.
Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.